Navigation Links
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
Date:8/12/2013

ROCKVILLE, Md., Aug. 12, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that it has appointed Jon Wigginton, M.D., as Senior Vice President, Clinical Development. Dr. Wigginton most recently held dual leadership roles at Bristol-Myers Squibb in clinical development and discovery research of its oncology programs.

"We are thrilled to welcome Jon to our team. He has demonstrated significant expertise in clinical development of oncology candidates throughout his years as both a clinical investigator and drug developer," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "In particular, his leadership in the innovative design of clinical studies for rapidly advancing the field of immune checkpoint therapeutics will prove valuable in maximizing the potential of our oncology portfolio."

"Dr. Wigginton is replacing our esteemed colleague, Anastasia Daifotis, M.D., who will continue on as a consultant through the end of 2013," added Dr. Koenig. "We thank Dr. Daifotis for her valuable contributions to MacroGenics, especially for her leadership in the clinical development of teplizumab for patients with type 1 diabetes. We wish her well in her future endeavors."

Dr. Wigginton was previously the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research and Executive Director, Discovery Medicine-Clinical Oncology at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno-Oncology portfolio including anti-PD-1 and anti-PD-L1. Prior to joining BMS, Dr. Wigginton was the Director of Clinical Oncology at Merck Research Laboratories, where he led early- and late-stage clinical development teams for small molecules and biologics. During his academic career, he held several positions at the National Cancer Institute Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch. Dr. Wigginton is also past president of the International Society for the Biological Therapy of Cancer (now SITC). He is the author of over 50 manuscripts and reviews and is the recipient of multiple awards for scientific accomplishment from sources including the NIH, NCI, USPHS, iSBTc, ISICR, Children's Cancer Foundation, Merck and BMS. Dr. Wigginton received his M.D. and B.S. in Biology, with distinction, from the University of Michigan.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. www.macrogenics.com

Statements made in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
2. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
3. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
4. Nephros Appoints John C. Houghton as President and Chief Executive Officer
5. Elsevier Appoints New President of Elsevier CPM Resource Center
6. GenWay Biotech Appoints New Vice President of Custom/OEM
7. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
8. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
11. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017 7D Surgical announced today that ... U.S. Food and Drug Administration (FDA) and a ... North American commercial launch of its innovative Machine-vision ... the 7D Surgical System.  The ... and machine vision algorithms to eliminate the long-standing ...
(Date:1/23/2017)... and Markets has announced the addition of the "Needle Free Drug ... report to their offering. ... Highlights: The report provides a detailed analysis ... Market forecasts till 2025, using estimated market values as the ... Regions and Countries Key developments and strategies observed in ...
(Date:1/23/2017)... Alberta , January 23, 2017 ... del riñón (r enal) y ... sola dosis de a pabetalone    ... hoy los resultados preliminares de un ensayo en fase ... con discapacidad de riñón (renal) severa. Los datos demostraron ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual Balances”: ... of Spiritual Balances” is the creation of published author, Pastor Bernard J. Weathers, pastor ... holds a bachelor degree in religious education and a master degree in theology. , ...
(Date:1/24/2017)... ... 23, 2017 , ... OSF Ventures, the corporate investment arm ... platform headquartered in Silicon Valley that connects startups to corporations and invests in ... three-year agreement to be a corporate sponsor of Plug and Play’s program for ...
(Date:1/24/2017)... ... January 23, 2017 , ... During the ... Carol Francis, Psychologist in the South Bay area , explained “Watching Women’s ... all people and by all people shines as a bright beacon of determination ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... translation and localization services for life science companies, has achieved ISO 17100:2015 ... TÜV SÜD America. ISO 17100 is the globally recognized standard that establishes ...
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters ... management and evaluation leaders with decades of experience who remain current practitioners in ... States healthcare system, there is a renewed demand for versatile, data-driven leadership.The American ...
Breaking Medicine News(10 mins):